Sezary Syndrome Cells Unlike Normal Circulating T Lymphocytes Fail to Migrate Following Engagement of NT1 Receptor

Journal of Investigative Dermatology

Volumn 122, Issue 1, 2004, Pages 111-118

  Magazin, Marilyn ^b   Poszepczynska Guigné, Ewa ^a   Bagot, Martine ^a   Boumsell, Laurence ^a   Pruvost, Christelle ^a   Chalon, Pascale ^b   Culouscou, Jean Michel ^b   Ferrara, Pascual ^a   Bensussan, Armand ^a,c  

^a HENRI MONDOR HOSPITAL   (France)

^b SANOFI   (France)

^c FACULTÉ DE MÉDECINE   (France)

Author keywords

Chemotaxis; Cutaneous T cell lymphoma; Neurotensin; Neurotensin receptors; Ssezary cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOATTRACTANT; CHEMOKINE; FOCAL ADHESION KINASE; MONOCLONAL ANTIBODY CD3; NEUROTENSIN; NEUROTENSIN 1 RECEPTOR; NEUROTENSIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; BLOOD; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL FUNCTION; CHEMOTAXIS; CONTROLLED STUDY; CYTOLOGY; CYTOPLASM; DRUG RESPONSE; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEZARY CELL; SEZARY SYNDROME; T LYMPHOCYTE;

EID: 1642493833     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2003.22131.x     Document Type: Article

References (49)

1. Amar S, Kitabgi P, Vincent JP: Activation of phosphatidylinositol turnover by neurotensin receptors in the human clonic adenocarcinoma cell line HT29. FEBS Lett 201:31-36, 1986
2. dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91:4331-4341, 1998
3. + cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 97:1388-1391, 2001
4. Boyden SV: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med 115:453-458, 1962
5. Brender C, Nielsen M, Kaltoft K, et al: STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 97:1056-1062, 2001
6. Carraway RE, Leeman SE: The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861, 1973
7. 2+-dependent adenylyl cyclase(s). Mol Cell Endocrinol 144:47-57, 1998
8. Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol 140:211-221, 1998
9. Chalon P, Vita N, Kaghad M, et al: Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 386:91-94, 1996
10. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL: Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 270:16995-16999, 1995
11. Choi SE, Chae HD, Park TJ, Ha H, Kim KT: Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. Br J Pharmacol 126:1050-1056, 1999
12. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268:233-239, 1995
13. Davis TP, Crowell S, McInturff B, Louis R, Gillespie T: Neurotensin may function as a regulatory peptide in small lung cancer. Peptides 12:17-24, 1991
14. De la Fuente M, Carrasco M, Del Rio M, Hernanz A: Modulation of murine lymphocyte functions by sulfated cholecystokinin octapeptide. Neuropeptides 32:225-233, 1998
15. Delaire S, Billard C, Tordjman R, Chédotal A, Elhabazi A, Bensussan A, Boumsell L: Biological activity of soluble CD100 II. Soluble CD100, similarly to H-Semall, inhibits immune cell migration. J Immunol 166:4348-4354, 2001
16. Delfau-Larue MH, Dalac S, Lepage E, Petrella T, Wechsler J, Farcet JP, Bagot M: Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 92:3376-3380, 1998
17. Delgado M, Pozo D, Martinez C, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies. J Immunol 162:2358-2367, 1999
18. Dorfman DM, Shahsafaei A: CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. Hum Pathol 33:330-334, 2002
19. Ehlers RA, Bonnor RM, Wang X, Hellmich MR, Evers BM: Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery 124:239-247, 1998
20. Evers BM, Bold RJ, Ehrenfried JA, Li J, Townsend CM, Klimpel GR: Characterization of functional neurotensin receptors on human lymphocytes. Surgery 116:134-140, 1994
21. Fargnoli MC, Edelson RL, Berger CL, Chimenti S, Couture C, Mustelin T, Halaban R: Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, syk and membrane associated Csk. Leukemia 11:1338-1346, 1997
22. Garrido JJ, Arahuetes RM, Hernanz A, De la Fuente M: Modulation by neurotensin and neuromedin N of adherence and chemotaxis capacity of murine lymphocytes. Regul Pept 41:27-37, 1992
23. Gilmore AP, Romer LH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7:1209-1224, 1996
24. Gully D, Canton M, Boigegrain R, et al: Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 90:65-69, 1993
25. Gully D, Labeeuw B, Boigegrain R, et al: Biochemical and pharmacological activities of SR142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 280:802-812, 1997
26. Hanks SK, Calab MB, Harper MC, Patel SK: Focal adhesion protein-tyrosine phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA 89:8487-8491, 1992
27. Hildebrand JD, Schaller MD, Parsons JT: Identification of sequences required for localization of focal adhesion kinase to focal adhesion. J Cell Biol 123:993-1005, 1993
28. Iwase K, Evers BM, Hellmich MR, Kim HJ, Higashide S, Gully D, Townsend CM: Indirect inhibitory effect of neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg Oncol 5:245-251, 1996
29. Jiménez C, Portela RA, Mellado M, et al: Role of PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol 151:249-261, 2000
30. Johnston JA, Taub DD, Lloyd AR, Conlon K, Oppenheim JJ, Kevlin DJ: Human T lymphocyte chemotaxis and adhesion induced by VIP. J Immunol 153:1762-1768, 1994
31. Kitabgi P, Carraway R, Van Rietschoten J, et al: Neurotensin specific binding to synaptic membranes from rat brain. Proc Natl Acad Sci USA 74:1846-1850, 1977
32. Leyton J, Garcia-Marin L, Jensen RT, Moody TW: Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. Eur J Pharmacol 442:179-186, 2002
33. Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M, Ginsberg MH: Binding of paxillin to α4 integrins modifies integrin-dependent biological responses. Nature 402:676-681, 1999
34. Mazella J, Zsürger N, Navarro V, et al: The 100-kDa neurotensin receptor is gp95/Sortolin, a non-G-protein-coupled receptor. J Biol Chem 273:26273-26276, 1998
35. Mitra SP, Carraway RE: Synergistic effects of neurotensin and β adrenergic agonist on 3′,5′-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells. Biochem Pharmacol 57:391-397, 1999
36. Owen JD, Ruest PJ, Fry DW, Hanks SK: Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk 2. Mol Cell Biol 19:4806-4818, 1999
37. + Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 96:1056-1063, 2000
38. Ramez M, Bagot M, Nikolova M, et al: Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes. J Invest Dermatol 117:687-693, 2001
39. Rozengurt E: Neuropeptides as cellular growth factors: Role of multiple signaling pathways. Eur J Invest 21:123-134, 1991
40. Savino W, Dardenne M: Immune-neuroendocrine interactions. Immunol Today 16:318-322, 1995
41. FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 89:192-196, 1992
42. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC: Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81-96, 1998
43. FAK. J Exp Med 182:1089-1100, 1995
44. Vita N, Laurent P, Lefort S, et al: Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 317:139-142, 1993
45. Vita N, Oury-Donat F, Chalon P, et al: Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol 360:265-272, 1998
46. Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997
47. Woll PJ, Rozengurt E: Multiple neuropeptides mobilise calcium in small cell lung cancer: Effects of vasopressin, bradykinin, cholecystokinin, galanin and neurotensin. Biochem Biophys Commun 164:66-73, 1989
48. Yawalker Y, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, Kupper TS: Profound loss of T cell receptor repertoire complexity in cutaneous T cell lymphoma. Blood June 26: 2003; DOI 10.1182/2003-04-1044 (publication online)
49. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik YA: Lack of phosphotyrosine phospohatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promotor. Am J Pathol 157:1137-1146, 2000